VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 14, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of novel cancer… Read More
August 13, 2019 53% of assessed patients have achieved a complete response; 41% have achieved stable disease VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 13, 2019 /PRNewswire/ — DelMar Pharmaceuticals,… Read More
Nasdaq Ticker Symbol “NLTX” to be effective Monday, August 12, 2019 SEATTLE, Aug. 09, 2019 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc.(“Neoleukin”), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced… Read More
SEATTLE, Aug. 07, 2019 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc.(“Neoleukin”), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, and Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), today announced that Jonathan G. Drachman, M.D., CEO,… Read More
Sophisticated computational platform enables new class of de novo protein therapeutics Lead program, NL-201, is a potent IL-2/IL-15 agonist with favorable therapeutic index Conference call on August 6, 2019 at 9 a.m…. Read More
